A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00100048
First received: December 22, 2004
Last updated: October 23, 2013
Last verified: October 2013
Results First Received: January 21, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Conditions: HIV Infections
Acquired Immunodeficiency Syndrome
Interventions: Drug: Comparator: MK0518 monotherapy
Drug: Comparator: MK0518 combination therapy
Drug: Comparator: efavirenz
Drug: Comparator: tenofovir
Drug: Comparator: lamivudine
Drug: Placebo monotherapy

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations

Primary therapy period:

For Part I (10 day monotherapy): 24-Jan-2005 to 04-May-2005

Part II (Dose Ranging): 14-Jun-2005 to 04-Oct-2006 (48 weeks); 14-Jun-2005 to 12-Jul-2010 (240 weeks)

Multicenter (29) in the United States (14) and Ex-US (15)


Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment

Patients with Human Immunodeficiency Virus (HIV) Ribonucleic acid (RNA) of at least 5000 copies/mL and cluster of differentiation 4 (CD4) cell counts of at least 100 cells/mm3. All patients must have met laboratory criteria.

206 enrolled; 5 from Cohort I did not continue to the combination phase. Therefore 201 entered the combination phase.


Reporting Groups
  Description
MK0518 100 mg b.i.d.

Cohort I-Monotherapy Phase

MK0518 100 mg twice daily (b.i.d.)

Cohort II Combined-Combination Therapy Phase

MK0518 100 mg + tenofovir + lamivudine

MK0518 200 mg b.i.d

Cohort I-Monotherapy Phase

MK0518 200 mg b.i.d

Cohort II Combined-Combination Therapy Phase

MK0518 200 mg + tenofovir + lamivudine

MK0518 400 mg b.i.d.

Cohort I-Monotherapy Phase

MK0518 400 mg b.i.d.

Cohort II Combined-Combination Therapy Phase

MK0518 400 mg + tenofovir + lamivudine

MK0518 600 mg b.i.d.

Cohort I-Monotherapy Phase

MK0518 600 mg b.i.d.

Cohort II Combined-Combination Therapy Phase

MK0518 600 mg + tenofovir + lamivudine

Placebo

Cohort I-Monotherapy Phase

Placebo to MK0518 b.i.d.

Efavirenz 600 mg q.h.s.

Cohort II Combined-Combination Therapy Phase

efavirenz 600 mg every night at bedtime (q.h.s.)


Participant Flow for 2 periods

Period 1:   Cohort I-Monotherapy Phase 10 Days
    MK0518 100 mg b.i.d.     MK0518 200 mg b.i.d     MK0518 400 mg b.i.d.     MK0518 600 mg b.i.d.     Placebo     Efavirenz 600 mg q.h.s.  
STARTED     7     7     6     8     7     0 [1]
Treated     7     7     6     8     7     0  
COMPLETED     7 [2]   7 [2]   6 [3]   8 [3]   7 [4]   0  
NOT COMPLETED     0     0     0     0     0     0  
[1] participants only assigned Efavirenz 600 mg q.h.s in Cohort II Combined-Combination Therapy Phase
[2] 7 Subjects Continued to Cohort II Combined-Combination Therapy Phase (48 Weeks)
[3] 6 Subjects Continued to Cohort II Combined-Combination Therapy Phase (48 Weeks)
[4] 4 Subjects Continued to Cohort II, as part of the Efavirenz 600 mg q.d. arm

Period 2:   Cohort I & II-Combination Therapy Phase
    MK0518 100 mg b.i.d.     MK0518 200 mg b.i.d     MK0518 400 mg b.i.d.     MK0518 600 mg b.i.d.     Placebo     Efavirenz 600 mg q.h.s.  
STARTED     41 [1]   40 [2]   41 [3]   40 [4]   0 [5]   39 [6]
Treated     39     40     41     40     0     38  
Never Treated     2 [7]   0     0     0     0     1 [7]
COMPLETED     27     31     28     30     0     26  
NOT COMPLETED     14     9     13     10     0     13  
Never Treated                 2                 0                 0                 0                 0                 1  
Adverse Event                 0                 1                 2                 0                 0                 1  
Lack of Efficacy                 1                 3                 0                 0                 0                 2  
Lost to Follow-up                 2                 1                 3                 2                 0                 3  
Withdrawal by Subject                 1                 2                 2                 5                 0                 4  
Other Reason                 7                 1                 4                 2                 0                 0  
Completed Base Study, Did Not Continue                 1                 1                 2                 0                 0                 2  
Laboratory Adverse Experience                 0                 0                 0                 1                 0                 0  
[1] 7 subjects from the Monotherapy Phase and 34 new subjects
[2] 7 subjects from the Monotherapy Phase and 33 new subjects
[3] 6 subjects from the Monotherapy Phase and 35 new subjects
[4] 8 subjects from the Monotherapy Phase and 32 new subjects
[5] participants only assigned Placebo in Cohort I-Monotherapy Phase.
[6] 4 subjects from the Monotherapy Phase (Placebo)and 35 new subjects
[7] Randomised in Cohort II did not start Period



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
MK0518 100 mg b.i.d.

Cohort I-Monotherapy Phase (10 Days)

MK0518 100 mg twice daily (b.i.d.)

Cohort II Combined-Combination Therapy Phase (48 Weeks) MK0518 100 mg b.i.d

MK0518 200 mg b.i.d

Cohort I-Monotherapy Phase (10 Days)

MK0518 200 mg b.i.d

Cohort II Combined-Combination Therapy Phase (48 Weeks) MK0518 200 mg + tenofovir + lamivudine

MK0518 400 mg b.i.d.

Cohort I-Monotherapy Phase (10 Days)

MK0518 400 mg b.i.d.

Cohort II Combined-Combination Therapy Phase (48 Weeks) MK0518 400 mg + tenofovir + lamivudine

MK0518 600 mg b.i.d.

Cohort I-Monotherapy Phase (10 Days)

MK0518 600 mg b.i.d.

Cohort II Combined-Combination Therapy Phase (48 Weeks) MK0518 600 mg + tenofovir + lamivudine

Placebo / Efavirenz 600 mg Once Daily (q.d.)

Cohort I-Monotherapy Phase (10 Days)

Placebo to MK0518 b.i.d.

Cohort II Combined-Combination Therapy Phase (48 Weeks)

Efavirenz + Tenofovir + Lamivudine

Total Total of all reporting groups

Baseline Measures
    MK0518 100 mg b.i.d.     MK0518 200 mg b.i.d     MK0518 400 mg b.i.d.     MK0518 600 mg b.i.d.     Placebo / Efavirenz 600 mg Once Daily (q.d.)     Total  
Number of Participants  
[units: participants]
  41     40     41     42     42     206  
Age [1]
[units: Years]
Mean ( Full Range )
           
Cohort I     46  
  ( 31 to 68 )  
  37  
  ( 22 to 57 )  
  41  
  ( 25 to 55 )  
  39  
  ( 30 to 49 )  
  36  
  ( 21 to 51 )  
  40  
  ( 21 to 68 )  
Cohort II     34  
  ( 19 to 58 )  
  31  
  ( 21 to 56 )  
  34  
  ( 19 to 50 )  
  36  
  ( 20 to 49 )  
  36  
  ( 22 to 54 )  
  35  
  ( 19 to 58 )  
Cohort I & II Combined     37  
  ( 19 to 68 )  
  34  
  ( 21 to 57 )  
  36  
  ( 19 to 55 )  
  37  
  ( 20 to 49 )  
  36  
  ( 22 to 54 )  
  36  
  ( 19 to 68 )  
Gender, Customized  
[units: participants]
           
Female (Cohort I)     0     1     0     0     1     2  
Male (Cohort I)     7     6     6     8     6     33  
Female (Cohort II)     6     10     4     11     8     39  
Male (Cohort II)     27     23     31     23     26     130  
Never Treated Cohort II     1     0     0     0     1     2  
Race/Ethnicity, Customized  
[units: participants]
           
White (Cohort I)     4     4     3     8     3     22  
Black (Cohort I)     1     1     0     0     0     2  
Asian (Cohort I)     0     0     0     0     1     1  
Hispanic (Cohort I)     2     2     3     0     3     10  
White (Cohort II)     4     10     11     8     10     43  
Black (Cohort II)     1     1     1     0     0     3  
Asian (Cohort II)     3     6     8     7     8     32  
Hispanic (Cohort II)     12     9     10     9     10     50  
Other (Cohort II)     13     7     5     10     6     41  
Never Treated (Cohort II)     1     0     0     0     1     2  
Cluster of differentiation 4 (CD4) Cell Count [1]
[units: cells/mm^3]
Mean ( Full Range )
           
Cohort I     415  
  ( 138 to 745 )  
  343  
  ( 149 to 624 )  
  256  
  ( 96 to 602 )  
  569  
  ( 241 to 1034 )  
  343  
  ( 115 to 599 )  
  394  
  ( 96 to 1034 )  
Cohort II     293  
  ( 76 to 736 )  
  292  
  ( 70 to 723 )  
  348  
  ( 95 to 1017 )  
  245  
  ( 99 to 734 )  
  276  
  ( 77 to 744 )  
  291  
  ( 70 to 1017 )  
Cohort I and II Combined     272  
  ( 76 to 758 )  
  277  
  ( 70 to 723 )  
  293  
  ( 95 to 1017 )  
  244  
  ( 99 to 786 )  
  225  
  ( 77 to 744 )  
  266  
  ( 70 to 1017 )  
Plasma Human Immunodeficiency Virus (HIV) Ribonucleic acid (RNA) [1]
[units: copies/mL]
Geometric Mean ( Full Range )
           
Cohort I     44989  
  ( 3890 to 225000 )  
  34143  
  ( 5420 to 168000 )  
  37728  
  ( 6850 to 152000 )  
  93911  
  ( 17100 to 388000 )  
  58412  
  ( 7630 to 456000 )  
  51496  
  ( 3890 to 456000 )  
Cohort II     65982  
  ( 4200 to 750000 )  
  73646  
  ( 7490 to 750000 )  
  47019  
  ( 2440 to 499000 )  
  61929  
  ( 3450 to 750000 )  
  76752  
  ( 7500 to 675000 )  
  63965  
  ( 2440 to 750000 )  
Cohort I and II Combined     58206  
  ( 4200 to 750000 )  
  64715  
  ( 7490 to 750000 )  
  43083  
  ( 2440 to 499000 )  
  57919  
  ( 3450 to 750000 )  
  67554  
  ( 3340 to 675000 )  
  57437  
  ( 2440 to 750000 )  
[1]

Cohort I Participants: MK0518 100 mg b.i.d. (7); MK0518 200 mg b.i.d. (7); MK0518 400 mg b.i.d. (6); MK0518 600 mg b.i.d. (8); Placebo Cohort (7)

Cohort II Participants: MK0518 100 mg b.i.d. (33); MK0518 200 mg b.i.d. (33); MK0518 400 mg b.i.d. (35); MK0518 600 mg b.i.d. (34); Efavirenz 600 mg q.d. (34)

Cohort I & II Participants Combined: MK0518 100 mg b.i.d. (39); MK0518 200 mg b.i.d. (40); MK0518 400 mg b.i.d. (41); MK0518 600 mg b.i.d. (40); Efavirenz 600 mg q.d. (38)




  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change From Baseline in Plasma Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) on Day 10 (Cohort I)   [ Time Frame: Baseline and Day 10 ]

2.  Primary:   Number of Patients With Clinical Adverse Experiences (CAEs) and Number of Patients With Serious CAEs at Day 10 (Cohort I)   [ Time Frame: 10 days ]

3.  Primary:   Number of Participants With HIV RNA Levels Below 400 Copies/mL at Week 24 (Cohort II)   [ Time Frame: Week 24 ]

4.  Primary:   Number of Patients With Clinical Adverse Experiences (CAEs)   [ Time Frame: 48 weeks ]

5.  Primary:   Number of Patients With Serious CAEs (Cohort I and II Combined)   [ Time Frame: 48 weeks ]

6.  Primary:   Number of Patients With Serious CAEs and Non-serious CAEs at Week 144   [ Time Frame: 144 Weeks ]

7.  Primary:   Number of Participants With Clinical Adverse Experiences (AEs)and Serious Adverse Experiences (SAEs)   [ Time Frame: Week 240 ]

8.  Primary:   Number of Participants With HIV RNA (Human Immunodeficiency Virus Ribonucleic Acid) Levels Below 50 Copies/mL at Week 240   [ Time Frame: Week 240 ]

9.  Secondary:   Number of Participants With HIV RNA Levels Below 50 Copies/mL at Week 24 (Cohort II)   [ Time Frame: Week 24 ]

10.  Secondary:   Change From Baseline in Plasma HIV RNA at Week 24 (Cohort II)   [ Time Frame: Baseline and Week 24 ]

11.  Secondary:   Change From Baseline in Cluster of Differentiation 4 (CD4) Cell Count at Week 24 (Cohort II)   [ Time Frame: Baseline and Week 24 ]

12.  Secondary:   Number of Patients With HIV RNA Level Below 50 Copies/mL and HIV RNA Level Below 400 Copies/mL at Week 96   [ Time Frame: 96 Weeks ]

13.  Secondary:   Change From Baseline in Plasma HIV RNA at Week 96   [ Time Frame: Baseline and Week 96 ]

14.  Secondary:   Change From Baseline in CD4 Cell Count at Week 96   [ Time Frame: Baseline and Week 96 ]

15.  Secondary:   Number of Participants With HIV RNA Levels Below 400 Copies/mL at Week 240   [ Time Frame: Week 240 ]

16.  Secondary:   Change From Baseline in Plasma HIV RNA at Week 240   [ Time Frame: Baseline and Week 240 ]

17.  Secondary:   Change From Baseline in CD4 (T-helper) Cell Count at Week 240   [ Time Frame: Baseline and Week 240 ]

18.  Other Pre-specified:   Number of Participants With HIV RNA Levels Below 400 Copies/mL at Week 48   [ Time Frame: 48 weeks ]

19.  Other Pre-specified:   Number of Patients With Drug-related CAEs   [ Time Frame: 48 weeks ]

20.  Other Pre-specified:   Number of Patients With Serious Drug-related CAEs   [ Time Frame: 48 Weeks ]

21.  Other Pre-specified:   Number of Patients That Discontinued With CAEs   [ Time Frame: 48 Weeks ]

22.  Other Pre-specified:   Number of Patients With Laboratory Adverse Experiences (LAEs)   [ Time Frame: 48 Weeks ]

23.  Other Pre-specified:   Number of Patients With Serious LAEs   [ Time Frame: 48 Weeks ]

24.  Other Pre-specified:   Number of Patients With Drug-related LAEs   [ Time Frame: 48 Weeks ]

25.  Other Pre-specified:   Number of Patients With Serious Drug-related LAEs   [ Time Frame: 48 Weeks ]

26.  Other Pre-specified:   Number of Patients That Discontinued With LAEs   [ Time Frame: 48 Weeks ]


  Serious Adverse Events


  Other Adverse Events
  Hide Other Adverse Events

Time Frame No text entered.
Additional Description No text entered.

Frequency Threshold
Threshold above which other adverse events are reported   5%  

Reporting Groups
  Description
MK-0518 b.i.d.

Cohort I-Monotherapy Phase (10 Days) MK0518 100, 200, 400, or 600 mg b.i.d.

Cohort II Combined-Combination Therapy Phase MK0518 100, 200, 400, or 600 mg + tenofovir + lamivudine

Efavirenz

EFV Combo Therapy Phase - Cohort II

efavirenz 600 mg daily at bedtime (qhs) + tenofovir + lamivudine

This arm included participants from Cohort I who were randomized to placebo.


Other Adverse Events
    MK-0518 b.i.d.     Efavirenz  
Total, other (not including serious) adverse events      
# participants affected / at risk     147/160     35/38  
Blood and lymphatic system disorders      
Anaemia † 1    
# participants affected / at risk     1/160 (0.63%)     2/38 (5.26%)  
# events     1     2  
Lymphadenopathy † 1    
# participants affected / at risk     2/160 (1.25%)     2/38 (5.26%)  
# events     3     2  
Eye disorders      
Conjunctivitis † 1    
# participants affected / at risk     7/160 (4.38%)     3/38 (7.89%)  
# events     8     3  
Gastrointestinal disorders      
Abdominal pain † 1    
# participants affected / at risk     10/160 (6.25%)     2/38 (5.26%)  
# events     11     2  
Anorectal discomfort † 1    
# participants affected / at risk     0/160 (0.00%)     2/38 (5.26%)  
# events     0     2  
Constipation † 1    
# participants affected / at risk     4/160 (2.50%)     2/38 (5.26%)  
# events     5     2  
Diarrhoea † 1    
# participants affected / at risk     42/160 (26.25%)     10/38 (26.32%)  
# events     67     19  
Flatulence † 1    
# participants affected / at risk     11/160 (6.88%)     1/38 (2.63%)  
# events     12     1  
Gastritis † 1    
# participants affected / at risk     7/160 (4.38%)     4/38 (10.53%)  
# events     8     4  
Nausea † 1    
# participants affected / at risk     35/160 (21.88%)     7/38 (18.42%)  
# events     40     8  
Toothache † 1    
# participants affected / at risk     9/160 (5.63%)     1/38 (2.63%)  
# events     10     1  
Vomiting † 1    
# participants affected / at risk     13/160 (8.13%)     7/38 (18.42%)  
# events     20     9  
General disorders      
Fatigue † 1    
# participants affected / at risk     13/160 (8.13%)     3/38 (7.89%)  
# events     17     4  
Influenza like illness † 1    
# participants affected / at risk     11/160 (6.88%)     3/38 (7.89%)  
# events     14     3  
Malaise † 1    
# participants affected / at risk     5/160 (3.13%)     3/38 (7.89%)  
# events     10     6  
Oedema peripheral † 1    
# participants affected / at risk     3/160 (1.88%)     2/38 (5.26%)  
# events     3     2  
Pyrexia † 1    
# participants affected / at risk     12/160 (7.50%)     2/38 (5.26%)  
# events     16     2  
Infections and infestations      
Anogenital warts † 1    
# participants affected / at risk     4/160 (2.50%)     3/38 (7.89%)  
# events     4     4  
Body tinea † 1    
# participants affected / at risk     6/160 (3.75%)     3/38 (7.89%)  
# events     7     5  
Bronchitis † 1    
# participants affected / at risk     23/160 (14.38%)     2/38 (5.26%)  
# events     31     3  
Gastroenteritis † 1    
# participants affected / at risk     7/160 (4.38%)     2/38 (5.26%)  
# events     10     7  
Herpes simplex † 1    
# participants affected / at risk     10/160 (6.25%)     0/38 (0.00%)  
# events     12     0  
Herpes zoster † 1    
# participants affected / at risk     9/160 (5.63%)     6/38 (15.79%)  
# events     9     6  
Influenza † 1    
# participants affected / at risk     3/160 (1.88%)     4/38 (10.53%)  
# events     3     6  
Localised infection † 1    
# participants affected / at risk     1/160 (0.63%)     2/38 (5.26%)  
# events     1     2  
Nasopharyngitis † 1    
# participants affected / at risk     30/160 (18.75%)     8/38 (21.05%)  
# events     57     13  
Onychomycosis † 1    
# participants affected / at risk     5/160 (3.13%)     4/38 (10.53%)  
# events     7     5  
Pharyngitis † 1    
# participants affected / at risk     19/160 (11.88%)     2/38 (5.26%)  
# events     21     3  
Sinusitis † 1    
# participants affected / at risk     16/160 (10.00%)     2/38 (5.26%)  
# events     19     5  
Syphilis † 1    
# participants affected / at risk     9/160 (5.63%)     3/38 (7.89%)  
# events     10     3  
Upper respiratory tract infection † 1    
# participants affected / at risk     39/160 (24.38%)     10/38 (26.32%)  
# events     74     13  
Injury, poisoning and procedural complications      
Joint sprain † 1    
# participants affected / at risk     3/160 (1.88%)     2/38 (5.26%)  
# events     3     2  
Investigations      
Alanine aminotransferase increased † 1    
# participants affected / at risk     13/160 (8.13%)     4/38 (10.53%)  
# events     29     10  
Aspartate aminotransferase increased † 1    
# participants affected / at risk     14/160 (8.75%)     6/38 (15.79%)  
# events     19     7  
Blood creatine phosphokinase increased † 1    
# participants affected / at risk     8/160 (5.00%)     4/38 (10.53%)  
# events     12     5  
Blood triglycerides increased † 1    
# participants affected / at risk     4/160 (2.50%)     2/38 (5.26%)  
# events     8     5  
Weight decreased † 1    
# participants affected / at risk     3/160 (1.88%)     2/38 (5.26%)  
# events     3     2  
Metabolism and nutrition disorders      
Overweight † 1    
# participants affected / at risk     9/160 (5.63%)     1/38 (2.63%)  
# events     10     1  
Musculoskeletal and connective tissue disorders      
Arthralgia † 1    
# participants affected / at risk     14/160 (8.75%)     1/38 (2.63%)  
# events     17     1  
Back pain † 1    
# participants affected / at risk     22/160 (13.75%)     2/38 (5.26%)  
# events     23     2  
Myalgia † 1    
# participants affected / at risk     7/160 (4.38%)     3/38 (7.89%)  
# events     7     3  
Pain in extremity † 1    
# participants affected / at risk     8/160 (5.00%)     3/38 (7.89%)  
# events     10     4  
Neoplasms benign, malignant and unspecified (incl cysts and polyps)      
Skin papilloma † 1    
# participants affected / at risk     8/160 (5.00%)     2/38 (5.26%)  
# events     9     3  
Nervous system disorders      
Disturbance in attention † 1    
# participants affected / at risk     4/160 (2.50%)     2/38 (5.26%)  
# events     4     2  
Dizziness † 1    
# participants affected / at risk     29/160 (18.13%)     13/38 (34.21%)  
# events     33     15  
Headache † 1    
# participants affected / at risk     33/160 (20.63%)     16/38 (42.11%)  
# events     56     31  
Lethargy † 1    
# participants affected / at risk     3/160 (1.88%)     2/38 (5.26%)  
# events     3     2  
Psychiatric disorders      
Abnormal dreams † 1    
# participants affected / at risk     13/160 (8.13%)     8/38 (21.05%)  
# events     13     9  
Anxiety † 1    
# participants affected / at risk     10/160 (6.25%)     4/38 (10.53%)  
# events     11     4  
Depression † 1    
# participants affected / at risk     20/160 (12.50%)     5/38 (13.16%)  
# events     23     6  
Insomnia † 1    
# participants affected / at risk     25/160 (15.63%)     5/38 (13.16%)  
# events     29     5  
Nightmare † 1    
# participants affected / at risk     1/160 (0.63%)     4/38 (10.53%)  
# events     1     4  
Respiratory, thoracic and mediastinal disorders      
Asthma † 1    
# participants affected / at risk     3/160 (1.88%)     2/38 (5.26%)  
# events     6     2  
Cough † 1    
# participants affected / at risk     8/160 (5.00%)     2/38 (5.26%)  
# events     10     2  
Nasal congestion † 1    
# participants affected / at risk     3/160 (1.88%)     2/38 (5.26%)  
# events     3     2  
Oropharyngeal pain † 1    
# participants affected / at risk     7/160 (4.38%)     3/38 (7.89%)  
# events     7     3  
Skin and subcutaneous tissue disorders      
Dermatitis † 1    
# participants affected / at risk     9/160 (5.63%)     2/38 (5.26%)  
# events     9     3  
Pruritus † 1    
# participants affected / at risk     12/160 (7.50%)     2/38 (5.26%)  
# events     14     3  
Rash † 1    
# participants affected / at risk     11/160 (6.88%)     2/38 (5.26%)  
# events     14     2  
Rash papular † 1    
# participants affected / at risk     0/160 (0.00%)     3/38 (7.89%)  
# events     0     3  
Seborrhoeic dermatitis † 1    
# participants affected / at risk     3/160 (1.88%)     2/38 (5.26%)  
# events     6     2  
Skin lesion † 1    
# participants affected / at risk     8/160 (5.00%)     3/38 (7.89%)  
# events     11     3  
Urticaria † 1    
# participants affected / at risk     2/160 (1.25%)     2/38 (5.26%)  
# events     2     2  
Events were collected by systematic assessment
1 Term from vocabulary, MedDRA 13.0



  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information